U.S. patent application number 11/775519 was filed with the patent office on 2008-04-17 for cannabimimetic indole derivatives.
Invention is credited to Hongfeng Deng, Alexandros Makriyannis.
Application Number | 20080090871 11/775519 |
Document ID | / |
Family ID | 34594179 |
Filed Date | 2008-04-17 |
United States Patent
Application |
20080090871 |
Kind Code |
A1 |
Makriyannis; Alexandros ; et
al. |
April 17, 2008 |
CANNABIMIMETIC INDOLE DERIVATIVES
Abstract
Novel cannabimimetic indole derivatives are presented which have
preferentially high affinities for one of the cannabinoid CB1 or
CB2 receptors. The improved receptor affinity makes these analogs
therapeutically useful as medications in individuals and animals
for treatment of pain, glaucoma, epilepsy, nausea associated with
chemotherapy.
Inventors: |
Makriyannis; Alexandros;
(Watertown, MA) ; Deng; Hongfeng; (Acton,
MA) |
Correspondence
Address: |
ALIX YALE & RISTAS LLP
750 MAIN STREET
SUITE 1400
HARTFORD
CT
06103
US
|
Family ID: |
34594179 |
Appl. No.: |
11/775519 |
Filed: |
July 10, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10982605 |
Nov 5, 2004 |
7241799 |
|
|
11775519 |
Jul 10, 2007 |
|
|
|
10111059 |
Oct 21, 2002 |
6900236 |
|
|
PCT/US00/28832 |
Oct 18, 2000 |
|
|
|
10982605 |
Nov 5, 2004 |
|
|
|
60159997 |
Oct 18, 1999 |
|
|
|
Current U.S.
Class: |
514/323 ;
514/415 |
Current CPC
Class: |
A61P 25/00 20180101;
A61P 27/06 20180101; A61P 29/00 20180101; A61P 35/00 20180101; C07D
401/06 20130101; C07D 209/12 20130101 |
Class at
Publication: |
514/323 ;
514/415 |
International
Class: |
A61K 31/404 20060101
A61K031/404; A61K 31/454 20060101 A61K031/454; A61P 25/00 20060101
A61P025/00; A61P 27/06 20060101 A61P027/06; A61P 29/00 20060101
A61P029/00; A61P 35/00 20060101 A61P035/00 |
Claims
1. A method of stimulating a CB1 or CB2 cannabinoid receptor in an
individual or animal comprising administering to the individual or
animal a therapeutically effective amount of a compound having the
formula: ##STR9## including any optical isomers and physiologically
acceptable salts thereof, wherein, Z may be in the 4-, 5-, 6- or
7-position and is selected from the group consisting of hydrogen,
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, azido,
cyano, isothiocyano, phenyl, hydroxy, methoxy and lower alkyl; X is
selected from the group consisting of halogen, hydrogen, hydroxy,
lower alkanoate, formyl, amino, cyano, and isothiocyano, and if Z
is not hydroxy, methoxy or lower alkyl then X may also be selected
from the group consisting of OTs and azido; R.sub.1 is selected
from the group consisting of saturated or unsaturated straight
carbon chains with a maximum length of seven carbon atoms,
saturated or unsaturated branched carbon chains with a maximum
length of seven carbon atoms; a cyclic aliphatic ring
interconnected to the indole-1 position with one or two carbon
atoms, a bicyclic aliphatic ring interconnected to the indole-1
position with one or two carbon atoms, and if Z is not hydroxy,
methoxy or lower alkyl then R.sub.1 may also be selected from a
heterocyclic ring interconnected to the indole-1 position with one
or two carbon atoms; R.sub.2 is selected from the group consisting
of H and lower alkyl; Y is selected from the group consisting of
carbonyl and CH.dbd.CH (cis or trans); and R.sub.3 is selected from
the group consisting of phenyl, naphthyl, 9-anthracenyl, adamantyl,
pyrenyl, phenyl with no more than two substituents selected from
the group consisting of halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and
isothiocyano, naphthyl with no more than two substituents selected
from the group consisting of halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano and isothiocyano, and 9-anthracenyl with no more than two
substituents selected from the group consisting of halogen, nitro,
nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower
alkyl, azido, cyano and isothiocyano.
2. The method of claim 1, wherein, Z may be in the 4-, 5-, 6- or
7-position and is selected from halogen, hydroxy, methoxy, or lower
alkyl; X is selected from halogen, hydrogen, hydroxy, lower
alkanoate, formyl, amino, cyano or isothiocyano; R.sub.1 is
selected from cyclic aliphatic rings interconnected to the indole-1
position with one or two carbon atoms or bicyclic aliphatic rings
interconnected to the indole-1 position with one or two carbon
atoms; R.sub.2 is selected from H or lower alkyl; Y is selected
from carbonyl or CH.dbd.CH (cis or trans); and R.sub.3 is selected
from phenyl, naphthyl, 9-anthracenyl, phenyl with no more than two
substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano or isothiocyano, naphthyl with no more than two substituents
selected from halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano or
isothiocyano, or 9-anthracenyl with no more than two substituents
selected from halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano or
isothiocyano.
3. The method of claim 1, wherein: Z may be in the 4-, 5-, 6- or
7-position and is selected from hydrogen, halogen, nitro, nitroso,
amino, alkylamino, dialkylamino, azido, cyano, isothiocyano and
phenyl; X is selected from halogen; hydrogen; hydroxy, lower
alkanoate, formyl, amino, cyano, isothiocyano, OTs and azido;
R.sub.1 is selected from a cyclic aliphatic ring interconnected to
the indole-1 position with one or two carbon atoms, a bicyclic
aliphatic ring interconnected to the indole-1 position with one or
two carbon atoms, and a heterocyclic ring interconnected to the
indole-1 position with one or two carbon atoms; R.sub.2 is selected
from H and lower alkyl; Y is selected from carbonyl and CH.dbd.CH
(cis or trans); and R.sub.3 is selected from phenyl, naphthyl,
9-anthracenyl, adamantyl, pyrenyl, phenyl with no more than two
substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano and isothiocyano, naphthyl with no more than two substituents
selected from halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and
isothiocyano and 9-anthracenyl with no more than two substituents
selected from halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and
isothiocyano.
4. The method of claim 1, wherein: Z may be in the 4-, 5-, 6- or
7-position and is selected from hydrogen, halogen, nitro, nitroso,
amino, alkylamino, dialkylamino, azido, cyano, isothiocyano or
phenyl; X is selected from halogen; hydrogen; hydroxy, lower
alkanoate, formyl, amino, cyano, isothiocyano, OTs or azido;
R.sub.1 is selected from a cyclic aliphatic ring interconnected to
the indole-1 position with one or two carbon atoms, a bicyclic
aliphatic ring interconnected to the indole-1 position with one or
two carbon atoms or a heterocyclic ring interconnected to the
indole-1 position with one or two carbon atoms; R.sub.2 is selected
from H or lower alkyl; Y is selected from carbonyl or CH.dbd.CH
(cis or trans); and R.sub.3 is selected from phenyl with two
substituents independently selected from halogen, nitro, nitroso,
amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl,
azido, cyano or isothiocyano.
5. The method of claim 1, wherein: Z is selected from hydrogen in
the 6 position or halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, azido, cyano, isothiocyano, phenyl, hydroxy, methoxy
or lower alkyl in the 4-, 5-, 6- or 7-position; R.sub.1 is a
heterocyclic ring interconnected to the indole-1 position with one
or two carbon atoms; R.sub.2 is selected from H or lower alkyl; Y
is selected from carbonyl or CH.dbd.CH (cis or trans); X is OTs;
and R.sub.3 is selected from phenyl, naphthyl or 9-anthracenyl
substituted with a first substituent selected from halogen,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido or
isothiocyano and a second substituent selected from nitro, nitroso,
amino, alkylamino, dialkylamino, azido and isothiocyano; or R.sub.3
is selected from phenyl, naphthyl or 9-anthracenyl substituted with
one to four substituents groups independently selected from nitro,
nitroso, amino, alkylamino, dialkylamino, azido and isothiocyano;
or R.sub.3 is selected from adamantyl or pyrenyl either
unsubstituted or substituted with no more than two substituents
selected from halogen, nitro, nitroso, amino, hydroxy, azido, cyano
and isothiocyano; and X is OTs.
6. The method of claim 1, wherein: Z is H in the 6 position;
R.sub.2 is hydrogen; Y is C.dbd.O; and R.sub.3 is phenyl
substituted with I and a second substituent selected from halogen,
nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy,
lower alkyl, azido, cyano or isothiocyano.
7. The method of claim 1, wherein one of the CB1 or CB2 cannabinoid
receptors is preferentially stimulated to a greater extent than the
other of the CB1 or CB2 cannabinoid receptors.
8. A pharmaceutical preparation comprising a) at least one member
selected from an excipient, a vehicle, an adjuvant, a flavoring, a
colorant, or a preservative and b) a therapeutically effective
amount of at least one compound of the formula below, including any
optical isomers, and physiologically acceptable salts thereof:
##STR10## wherein, Z may be in the 4-, 5-, 6- or 7-position and is
selected from hydrogen, halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, azido, cyano, isothiocyano, phenyl, hydroxy, methoxy
or lower alkyl; X is selected from halogen; hydrogen; hydroxy,
lower alkanoate, formyl, amino, cyano or isothiocyano, and if Z is
not hydroxy, methoxy or lower alkyl then X may also be OTs or
azido; R.sub.1 is selected from a cyclic aliphatic ring
interconnected to the indole-1 position with one or two carbon
atoms, a bicyclic aliphatic ring interconnected to the indole-1
position with one or two carbon atoms, and if Z is not hydroxy,
methoxy or lower alkyl then R.sub.1 may also be a heterocyclic ring
interconnected to the indole-1 position with one or two carbon
atoms; R.sub.2 is selected from H or lower alkyl; Y is selected
from carbonyl or CH.dbd.CH (cis or trans); and R.sub.3 is selected
from phenyl; naphthyl; 9-anthracenyl; adamantyl; pyrenyl; phenyl
with no more than two substituents selected from halogen, nitro,
nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower
alkyl, azido, cyano or isothiocyano; naphthyl with no more than two
substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano or isothiocyano; or 9-anthracenyl with no more than two
substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano or isothiocyano.
9. The pharmaceutical preparation of claim 8, wherein: Z may be in
the 4-, 5-, 6- or 7-position and is selected from hydrogen,
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, azido,
cyano, isothiocyano or phenyl; X is selected from halogen;
hydrogen; hydroxy, lower alkanoate, formyl, amino, cyano,
isothiocyano, OTs or azido; R.sub.1 is selected from a cyclic
aliphatic ring interconnected to the indole-1 position with one or
two carbon atoms, a bicyclic aliphatic ring interconnected to the
indole-1 position with one or two carbon atoms or a heterocyclic
ring interconnected to the indole-1 position with one or two carbon
atoms; R.sub.2 is selected from H or lower alkyl; Y is selected
from carbonyl or CH.dbd.CH (cis or trans); and R.sub.3 is selected
from phenyl with two substituents independently selected from
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy,
methoxy, lower alkyl, azido, cyano or isothiocyano.
10. The pharmaceutical preparation of claim 8, wherein: Z is
selected from hydrogen in the 6 position or halogen, nitro,
nitroso, amino, alkylamino, dialkylamino, azido, cyano,
isothiocyano, phenyl, hydroxy, methoxy or lower alkyl in the 4-,
5-, 6- or 7-position; R.sub.1 is a heterocyclic ring interconnected
to the indole-1 position with one or two carbon atoms; R.sub.2 is
selected from H or lower alkyl; Y is selected from carbonyl or
CH.dbd.CH (cis or trans); X is OTs; and R.sub.3 is selected from
phenyl, naphthyl or 9-anthracenyl substituted with a first
substituent selected from halogen, alkylamino, dialkylamino,
hydroxy, methoxy, lower alkyl, azido or isothiocyano and a second
substituent selected from nitro, nitroso, amino, alkylamino,
dialkylamino, azido or isothiocyano; or R.sub.3 is selected from
phenyl, naphthyl or 9-anthracenyl substituted with one to four
substituents groups independently selected from nitro, nitroso,
amino, alkylamino, dialkylamino, azido or isothiocyano; or R.sub.3
is selected from adamantyl or pyrenyl either unsubstituted or
substituted with no more than two substituents selected from
halogen, nitro, nitroso, amino, hydroxy, azido, cyano or
isothiocyano.
11. The pharmaceutical preparation of claim 8, wherein: Z is H in
the 6 position; R.sub.2 is hydrogen; Y is C.dbd.O; and R.sub.3 is
phenyl substituted with I and a second substituent selected from
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy,
methoxy, lower alkyl, azido, cyano or isothiocyano.
12. The pharmaceutical preparation of claim 8, wherein, Z may be in
the 4-, 5-, 6- or 7-position and is selected from halogen, hydroxy,
methoxy, or lower alkyl; X is selected from halogen, hydrogen,
hydroxy, lower alkanoate, formyl, cyano or isothiocyano; R.sub.1 is
selected from cyclic aliphatic rings interconnected to the indole-1
position with one or two carbon atoms or bicyclic aliphatic rings
interconnected to the indole-1 position with one or two carbon
atoms; R.sub.2 is selected from H or lower alkyl; Y is selected
from carbonyl or CH.dbd.CH (cis or trans); and R.sub.3 is selected
from phenyl, naphthyl, 9-anthracenyl, phenyl with no more than two
substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano or isothiocyano, naphthyl with no more than two substituents
selected from halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano or
isothiocyano, and 9-anthracenyl with no more than two substituents
selected from halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano or
isothiocyano.
13. The pharmaceutical preparation of claim 8, wherein, Z may be in
the 4-, 5-, 6- or 7-position and is selected from hydrogen,
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, azido,
cyano, isothiocyano and phenyl; X is selected from halogen;
hydrogen; hydroxy, lower alkanoate, formyl, amino, cyano,
isothiocyano, OTs and azido; R.sub.1 is selected from a cyclic
aliphatic ring interconnected to the indole-1 position with one or
two carbon atoms, a bicyclic aliphatic ring interconnected to the
indole-1 position with one or two carbon atoms, and a heterocyclic
ring interconnected to the indole-1 position with one or two carbon
atoms; R.sub.2 is selected from H and lower alkyl; Y is selected
from carbonyl and CH.dbd.CH (cis or trans); and R.sub.3 is selected
from phenyl, naphthyl, 9-anthracenyl, adamantyl, pyrenyl, phenyl
with no more than two substituents selected from halogen, nitro,
nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower
alkyl, azido, cyano and isothiocyano, naphthyl with no more than
two substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano and isothiocyano and 9-anthracenyl with no more than two
substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano and isothiocyano.
14. The pharmaceutical preparation of claim 8, wherein the compound
is in isolated and substantially purified form.
15. A method of treating a condition susceptible to stimulation of
a cannabinoid receptor in an individual or animal having the
condition comprising administering to the individual or animal a
pharmaceutical preparation comprising a) at least one member
selected from an excipient, a vehicle, an adjuvant, a flavoring, a
colorant, or a preservative and b) a therapeutically effective
amount of at least one compound of the formula below, including any
optical isomers, and physiologically acceptable salts thereof:
##STR11## wherein, Z may be in the 4-, 5-, 6- or 7-position and is
selected from hydrogen, halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, azido, cyano, isothiocyano, phenyl, hydroxy, methoxy
or lower alkyl; X is selected from halogen; hydrogen; hydroxy,
lower alkanoate, formyl, amino, cyano or isothiocyano, and if Z is
not hydroxy, methoxy or lower alkyl then X may also be OTs or
azido; R.sub.1 is selected from a cyclic aliphatic ring
interconnected to the indole-1 position with one or two carbon
atoms, a bicyclic aliphatic ring interconnected to the indole-1
position with one or two carbon atoms, and if Z is not hydroxy,
methoxy or lower alkyl then R.sub.1 may also be a heterocyclic ring
interconnected to the indole-1 position with one or two carbon
atoms; R.sub.2 is selected from H or lower alkyl; Y is selected
from carbonyl or CH.dbd.CH (cis or trans); and R.sub.3 is selected
from phenyl; naphthyl; 9-anthracenyl; adamantyl; pyrenyl; phenyl
with no more than two substituents selected from halogen, nitro,
nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy, lower
alkyl, azido, cyano or isothiocyano; naphthyl with no more than two
substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano or isothiocyano; or 9-anthracenyl with no more than two
substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano or isothiocyano.
16. The method of claim 15, wherein: Z may be in the 4-, 5-, 6- or
7-position and is selected from hydrogen, halogen, nitro, nitroso,
amino, alkylamino, dialkylamino, azido, cyano, isothiocyano or
phenyl; X is selected from halogen; hydrogen; hydroxy, lower
alkanoate, formyl, amino, cyano, isothiocyano, OTs or azido;
R.sub.1 is selected from a cyclic aliphatic ring interconnected to
the indole-1 position with one or two carbon atoms, a bicyclic
aliphatic ring interconnected to the indole-1 position with one or
two carbon atoms or a heterocyclic ring interconnected to the
indole-1 position with one or two carbon atoms; R.sub.2 is selected
from H or lower alkyl; Y is selected from carbonyl or CH.dbd.CH
(cis or trans); and R.sub.3 is selected from phenyl with two
substituents independently selected from halogen, nitro, nitroso,
amino, alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl,
azido, cyano or isothiocyano.
17. The method of claim 15, wherein: Z is selected from hydrogen in
the 6 position or halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, azido, cyano, isothiocyano, phenyl, hydroxy, methoxy
or lower alkyl in the 4-, 5-, 6- or 7-position; R.sub.1 is a
heterocyclic ring interconnected to the indole-1 position with one
or two carbon atoms; R.sub.2 is selected from H or lower alkyl; Y
is selected from carbonyl or CH.dbd.CH (cis or trans); X is OTs;
and R.sub.3 is selected from phenyl, naphthyl or 9-anthracenyl
substituted with a first substituent selected from halogen,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido or
isothiocyano and a second substituent selected from nitro, nitroso,
amino, alkylamino, dialkylamino, azido or isothiocyano; or R.sub.3
is selected from phenyl, naphthyl or 9-anthracenyl substituted with
one to four substituents groups independently selected from nitro,
nitroso, amino, alkylamino, dialkylamino, azido or isothiocyano; or
R.sub.3 is selected from adamantyl or pyrenyl either unsubstituted
or substituted with no more than two substituents selected from
halogen, nitro, nitroso, amino, hydroxy, azido, cyano or
isothiocyano.
18. The method of claim 15, wherein: Z is H in the 6 position;
R.sub.2 is hydrogen; Y is C.dbd.O; and R.sub.3 is phenyl
substituted with I and a second substituent selected from halogen,
nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy, methoxy,
lower alkyl, azido, cyano or isothiocyano.
19. The method of claim 15, wherein, Z may be in the 4-, 5-, 6- or
7-position and is selected from halogen, hydroxy, methoxy, or lower
alkyl; X is selected from halogen, hydrogen, hydroxy, lower
alkanoate, formyl, cyano or isothiocyano; R.sub.1 is selected from
cyclic aliphatic rings interconnected to the indole-1 position with
one or two carbon atoms or bicyclic aliphatic rings interconnected
to the indole-1 position with one or two carbon atoms; R.sub.2 is
selected from H or lower alkyl; Y is selected from carbonyl or
CH.dbd.CH (cis or trans); and R.sub.3 is selected from phenyl,
naphthyl, 9-anthracenyl, phenyl with no more than two substituents
selected from halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano or
isothiocyano, naphthyl with no more than two substituents selected
from halogen, nitro, nitroso, amino, alkylamino, dialkylamino,
hydroxy, methoxy, lower alkyl, azido, cyano or isothiocyano, and
9-anthracenyl with no more than two substituents selected from
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy,
methoxy, lower alkyl, azido, cyano or isothiocyano.
20. The method of claim 15, wherein, Z may be in the 4-, 5-, 6- or
7-position and is selected from hydrogen, halogen, nitro, nitroso,
amino, alkylamino, dialkylamino, azido, cyano, isothiocyano and
phenyl; X is selected from halogen; hydrogen; hydroxy, lower
alkanoate, formyl, amino, cyano, isothiocyano, OTs and azido;
R.sub.1 is selected from a cyclic aliphatic ring interconnected to
the indole-1 position with one or two carbon atoms, a bicyclic
aliphatic ring interconnected to the indole-1 position with one or
two carbon atoms, and a heterocyclic ring interconnected to the
indole-1 position with one or two carbon atoms; R.sub.2 is selected
from H and lower alkyl; Y is selected from carbonyl and CH.dbd.CH
(cis or trans); and R.sub.3 is selected from phenyl, naphthyl,
9-anthracenyl, adamantyl, pyrenyl, phenyl with no more than two
substituents selected from halogen, nitro, nitroso, amino,
alkylamino, dialkylamino, hydroxy, methoxy, lower alkyl, azido,
cyano and isothiocyano, naphthyl with no more than two substituents
selected from halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and
isothiocyano and 9-anthracenyl with no more than two substituents
selected from halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and
isothiocyano.
21. The method of claim 15, wherein the compound is in isolated and
substantially purified form.
22. The method of claim 15, wherein the condition is selected from
pain, peripheral pain, glaucoma, epilepsy, nausea, AIDS Wasting
Syndrome, cancer, neurodegenerative diseases, Multiple Sclerosis,
Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease,
mental disorder, schizophrenia, depression; endotoxic shock,
hypotensive shock; appetite modulation, fertility reduction,
Tourette's syndrome, and inflammation.
23. The method of claim 15, wherein the condition is selected from
pain, peripheral pain and inflammation.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is continuation of U.S. application Ser.
No. 10/982,605, filed Nov. 5, 2004, which is a divisional of U.S.
application Ser. No. 10/111,059, filed Oct. 21, 2002, now U.S. Pat.
No. 6,900,236, which is the national phase of International
Application No. PCT/US00/28832, filed Oct. 18, 2000, which claims
the benefit of U.S. Provisional Patent Application No.60/159,997,
filed Oct. 18, 1999, the contents of each of which are incorporated
herein by reference in their entirety.
FIELD OF THE INVENTION
[0002] The present invention relates generally to cannabinoid
analogs and is more particularly concerned with new and improved
indole cannabinoid analogs exhibiting high binding affinities for
cannabinoid receptors, pharmaceutical preparations employing these
analogs and methods of administering therapeutically effective
amounts of the preparations to provide a physiological effect.
BACKGROUND OF THE INVENTION
[0003] Classical cannabinoids such as the marijuana derived
cannabinoid .DELTA..sup.9-tetrahydrocannabinol, (.DELTA..sup.9-THC)
produce their pharmacological effects via interaction with specific
cannabinoid receptors in the body. So far, two cannabinoid
receptors have been characterized: CB1, a central receptor found in
the mammalian brain and peripheral tissues and CB2, a peripheral
receptor found only in the peripheral tissues. Compounds that are
agonists or antagonists for one or both of these receptors have
been shown to provide a variety of pharmacological effects. See,
for example, Pertwee, R. G., Pharmacology of cannabinoid CB1 and
CB2 receptors, Pharmacol. Ther., (1997) 74:129-180 and Di Marzo,
V., Melck, D., Bisogno, T., DePetrocellis, L., Endocannabinoids:
endogenous cannabinoid receptor ligands with neuromodulatory
action, Trends Neurosci. (1998) 21:521-528.
[0004] There is considerable interest in developing cannabinoid
analogs possessing high affinity for one of the CB1 or CB2
receptors and/or metabolic stability. Such analogs may offer a
rational therapeutic approach to a variety of disease states. One
class of cannabimimetic analogs encompasses indole derivatives such
as the well known aminoalkylindoles represented by WIN 55212-2
{(R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]-pyrrolo[1,2,3-de-
]-1,4-benzoxazin-6-yl](1-napthalenyl)methanone}. Aminoalkylindoles
of this type typically have a carbon linked alkylheterocyclic
substituent at the indole-1 position, which is believed to be
important for their cannabimimetic activities. These known
materials are not selective for preferential activation of one of
the CB1 or CB2 receptors.
SUMMARY OF THE INVENTION
[0005] Aminoalkylindoles have been found to act as agonists for the
CB1 and CB2 receptors and occasionally as antagonists for the CB1
and CB2 receptors. The invention includes compounds selective for
either the CB1 or CB2 receptors. Further, some of the compounds
have agonistic or antagonistic properties.
[0006] One aspect of the invention includes several novel
aminoalkylindole cannabinoid analogs and physiologically acceptable
salts thereof. In one embodiment of the invention, straight carbon
chains were introduced to the indole-1 position. Different
functional groups were also introduced to the straight carbon
chains. This embodiment is shown as A. ##STR1##
[0007] Z may be in the 4-, 5-, 6- or 7-position and is selected
from the group consisting of nitro; nitroso; amino; alkylamino;
dialkylamino; azido (N.sub.3); cyano; isothiocyano and phenyl.
[0008] X is selected from the group consisting of halogen;
hydrogen; hydroxy; low alkanoate; formyl; amino; cyano;
isothiocyano and azido.
[0009] R.sub.1 is selected from the group consisting of saturated
or unsaturated straight carbon chains with a maximum length of
seven carbon atoms; saturated or unsaturated branched carbon chains
with a maximum length of seven carbon atoms; cyclic aliphatic rings
interconnected to the indole-1 position with one or two carbon
atoms; bicyclic aliphatic rings interconnected to the indole-1
position with one or two carbon atoms; and heterocyclic rings
interconnected to the indole-1 position with one or two carbon
atoms.
[0010] R.sub.2 is selected from the group consisting of H and lower
alkyl.
[0011] Y is selected from the group consisting of carbonyl and
CH.dbd.CH (cis or trans).
[0012] R.sub.3 is selected from the group consisting of phenyl;
napthyl; 9-anthracenyl; adamantyl; pyrenyl; phenyl with no more
than two substituents selected from the group consisting of
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy,
methoxy, lower alkyl, azido, cyano and isothiocyano; napthyl with
no more than two substituents selected from the group consisting of
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy,
methoxy, lower alkyl, azido, cyano and isothiocyano; and
9-anthracenyl with no more than two substituents selected from the
group consisting of halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and
isothiocyano.
[0013] The analogs of this embodiment show high binding affinities
for the CB1 and CB2 cannabinoid receptors. More importantly, some
of these compounds show not only comparable cannabimimetic activity
with the compound WIN 55212-2 but also a surprisingly higher
selectivity for one of the CB1 or CB2 receptors. More specifically,
the inventive analogs showed similar or higher receptor binding
affinity than the well-known indole cannabinoid WIN 55212-2.
[0014] Another embodiment of the invention is shown as B. In this
embodiment the functionalities of the novel cannabimimetic indole
analogs were modified in the indole-3 and/or indole-6 positions.
##STR2##
[0015] Z may be in the 4-, 5-, 6- or 7-position and is selected
from the group consisting of halogen; hydroxy; methoxy and lower
alkyl.
[0016] X is selected from the group consisting of hydrogen;
hydroxy; lower alkanoate; formyl; amino; cyano and
isothiocyano.
[0017] R.sub.1 is selected from the group consisting of saturated
or unsaturated straight carbon chains with a maximum length of
seven carbon atoms; saturated or unsaturated branched carbon chains
with a maximum length of seven carbon atoms; cyclic aliphatic rings
interconnected to the indole-1 position with one or two carbon
atoms; and bicyclic aliphatic rings interconnected to the indole-1
position with one or two carbon atoms.
[0018] R.sub.2 is selected from the group consisting of H and lower
alkyl.
[0019] Y is selected from the group consisting of carbonyl and
CH.dbd.CH (cis or trans).
[0020] R.sub.3 is selected from the group consisting of phenyl;
napthyl; 9-anthracenyl; adamantyl; pyrenyl; phenyl with no more
than two substituents selected from the group consisting of
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy,
methoxy, lower alkyl, azido, cyano and isothiocyano; napthyl with
no more than two substituents selected from the group consisting of
halogen, nitro, nitroso, amino, alkylamino, dialkylamino, hydroxy,
methoxy, lower alkyl, azido, cyano and isothiocyano, and
9-anthracenyl with no more than two substituents selected from the
group consisting of halogen, nitro, nitroso, amino, alkylamino,
dialkylamino, hydroxy, methoxy, lower alkyl, azido, cyano and
isothiocyano.
[0021] The analogs of this embodiment are surprisingly potent
cannabimimetic compounds with high CB1 and/or CB2 selectivity.
[0022] Since CB2 selective cannabinoids are able to activate the
CB2 receptor and thereby modulate the immune system with little
psychoactivity or other CNS effects, these analogs are possible
therapeutic agents. Additionally, some of the iodide and fluoride
containing analogs are potential radioactive probes for imaging in
vivo the distribution of cannabinoid receptors. The azido modified
analogs are excellent affinity probes for characterizing binding
pockets of cannabinoid receptors.
[0023] The analogs disclosed herein are relatively easy to
manufacture. Additionally these analogs have better physiochemical
properties than naturally occurring cannabinoids. Thus, the novel
cannabimimetic indole derivatives described herein, and
physiologically acceptable salts thereof, represent potentially
useful materials for providing a physiological effect to treat
pain, peripheral pain, glaucoma, epilepsy, nausea such as
associated with cancer chemotherapy, AIDS Wasting Syndrome, cancer,
neurodegenerative diseases including Multiple Sclerosis,
Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease,
mental disorders such as Schizophrenia and depression; to prevent
or reduce endotoxic shock and hypotensive shock; to modulate
appetite; to reduce fertility; to prevent or reduce diseases
associated with motor function such as Tourette's syndrome; to
prevent or reduce inflammation; to provide neuroprotection and to
effect memory enhancement.
[0024] The novel cannabimimetic indole derivatives described herein
also provide useful materials for testing the cannabinoid system.
Thus, another aspect of the invention is the administration of a
therapeutically effective amount of an inventive compound, or a
physiologically acceptable salt thereof, to an individual or animal
to provide a physiological effect.
DESCRIPTION OF SOME PREFERRED EMBODIMENTS
[0025] As used herein, a "therapeutically effective amount" of a
compound, is the quantity of a compound which, when administered to
an individual or animal, results in a sufficiently high level of
that compound in the individual or animal to cause a discernible
increase or decrease in stimulation of cannabinoid receptors.
Physiological effects that result from cannabinoid receptor
stimulation include analgesia, decreased nausea resulting from
chemotherapy, sedation and increased appetite. Other physiological
functions include relieving intraocular pressure in glaucoma
patients and suppression of the immune system Typically, about 10
mg/day to about 1,000 mg/day is a possible "therapeutically
effective amount" for the inventive compounds.
[0026] As used herein, an "individual" refers to a human. An
"animal" refers to, for example, veterinary animals, such as dogs,
cats, horses and the like, and farm animals, such as cows, pigs and
the like.
[0027] The compound of the present invention can be administered by
a variety of known methods, including orally, rectally, or by
parenteral routes (e.g., intramuscular, intravenous, subcutaneous,
nasal or topical). The form in which the compounds are administered
will be determined by the route of administration. Such forms
include, but are not limited to, capsular and tablet formulations
(for oral and rectal administration), liquid formulations (for
oral, intravenous, intramuscular, transdermal or subcutaneous
administration) and slow releasing microcarriers (for rectal,
intramuscular or intravenous administration). The formulations can
also contain a physiologically acceptable vehicle and optional
adjuvants, flavorings, colorants and preservatives. Suitable
physiologically to acceptable vehicles may include, for example,
saline, sterile water, Ringer's solution, and isotonic sodium
chloride solutions. The specific dosage level of active ingredient
will depend upon a number of factors, including, for example,
biological activity of the particular preparation, age, body
weight, sex and general health of the individual being treated.
[0028] The inventive cannabinoid analogs are generally described by
the structural formulas previously disclosed. The following
examples are given for purposes of illustration only in order that
the present invention may be more fully understood. These examples
are not intended to limit in any way the practice of the invention.
The prepared cannabimimetic indole derivatives can generally be
described with reference to structural formulas 1 and 2 below and
include physiologically acceptable salts thereof.
[0029] The inventive cannabimimetic indole derivatives of
structural formula 1 include both racemics and two enantiomers.
##STR3##
[0030] Z is in the indole-6 position and is selected from the group
consisting of H; NO.sub.2; NH.sub.2; N.sub.3 and NCS.
[0031] R.sub.1 is a heterocyclic ring interconnected to the
indole-1 position with one carbon atom.
[0032] X is hydrogen.
[0033] R.sub.2 is selected from the group consisting of H and
methyl.
[0034] Y is carbonyl.
[0035] R.sub.3 is selected from the group consisting of phenyl;
napthyl; adamantanyl; pyrenyl and substituted versions of any of
the above.
[0036] The inventive materials of structural formula 1 are listed
in TABLE 1. It should be noted that R, for all of the materials of
TABLE 1 was 1-(N-Methyl-2-piperidinyl)methyl. All of the materials
of TABLE 1 have a chiral center and the binding affinities of the
materials of TABLE 1 were obtained by evaluating their racemic
samples. TABLE-US-00001 TABLE 1 K.sub.I nM analog Z R.sub.2 R.sub.3
CB1 CB2 AM664 N0.sub.2 CH.sub.3 2-iodophenyl 40 80.0 AM665 NH.sub.2
CH.sub.3 2-iodophenyl 206 20.3 AM671 N.sub.3 CH.sub.3 Phenyl 155
59.1 AM684 NCS CH.sub.3 Phenyl 181 44.8 AM1215 N.sub.3 CH.sub.3
2-iodophenyl 40.7 21.9 AM1216 NCS CH.sub.3 2-iodophenyl 210 25.2
AM2209 N.sub.3 H 5-azido-2-iodophenyl 48.8 41.8 AM2223 NCS H
5-isothiocyanato-2- 64.8 29.9 iodophenyl AM1221 N0.sub.3 CH.sub.3
1-naphthyl 52.3 0.28 AM1225 NH.sub.3 CH.sub.3 1-naphthyl 439.6 38.5
AM1231 N.sub.3 CH.sub.3 1-naphthyl 31.2 34.2 AM1218 N0.sub.2 H
1-naphthyl 11.2 3.98 AM1219 NH.sub.2 H 1-naphthyl 96.6 31.3 AM1224
N.sub.3 H 1-naphthyl 20.2 0.73 AM1217 NCS H 1-naphthyl 255 81.5
AM1299 H H 4-nitro-1-naphthyl 12.4 13.5 AM1296 H H 1-naphthyl 7.57
3.88 AM1220 H H 1-naphthyl 3.88 73.4 AM2212 N.sub.3 H
4-iodo-1-naphthyl 31.0 2.90 AM2215 NCS H
4-isothiocyanato-1-naphthyl 235 99.6 AM1248 H H adamantanyl 100 332
AM1253 H H 2-pyrenyl 60.3 126
[0037] ##STR4##
[0038] Z is in the indole-6 position and is selected from the group
consisting of hydrogen; NO.sub.2; NH.sub.2 and halogen.
[0039] X is selected from the group consisting of halogen; H; OH;
OCOCH.sub.3; OTs; NCS; OAc and CN.
[0040] R.sub.1 is a saturated lower alkane with a maximum length of
seven carbon atoms.
[0041] R.sub.2 is selected from the group consisting of H and
methyl.
[0042] Y is carbonyl.
[0043] R.sub.3 is selected from the group consisting of phenyl;
napthyl; and substituted versions of any of the above.
[0044] The inventive materials of structural formula 1 are listed
in TABLE 2. R.sub.1 lists the number of carbon atoms in the chain
at that position. TABLE-US-00002 TABLE 2 K.sub.I nM analog Z
R.sub.1 X R.sub.2 R.sub.3 CB1 CB2 AM683 H 4 H CH.sub.3 2-iodophenyl
272 281 AM669 H 5 H CH.sub.3 2-iodophenyl 47.2 38.6 AM682 H 6 H
CH.sub.3 2-iodophenyl 332 693 AM672 H 7 H CH.sub.3 2-iodophenyl
1603 1511 AM689 H 5 OCOCH.sub.3 CH.sub.3 2-iodophenyl 2279 1019
AM690 H 5 OH CH.sub.3 2-iodophenyl 4850 1972 AM2227 H 5 OTs
CH.sub.3 2-iodophenyl 1024 2968 AM2229 H 5 I CH.sub.3 2-iodophenyl
116.5 46.2 AM2230 H 5 NCS CH.sub.3 2-iodophenyl 195 29.5 AM2225 H 5
F CH.sub.3 2-iodophenyl 5.97 3.8 AM679 H 5 H H 2-iodophenyl 13.5
49.5 AM692 H 5 OCOCH.sub.3 H 2-iodophenyl 2656 1519 AM693 H 5 OH H
2-iodophenyl 835 526 AM697 H 5 OTs H 2-iodophenyl 1306 1116 AM698 H
5 I H 2-iodophenyl 135.8 314.7 AM1201 H 5 NCS H 2-iodophenyl 106
110 AM694 H 5 F H 2-iodophenyl 0.08 1.44 AM1202 H 5 H H 2-iodo-
98.9 22.9 5-nitrophenyl AM1203 H 5 H H 2-iodo- 63.6 88.9
5-aminophenyl AM1204 H 5 H H 2-iodo-5- 5659 3353 isothiocyanophenyl
AM1205 H 5 H H 2-iodo- 116.9 195.7 5-azidophenyl AM1206 H 5 H H
2,5-diiodophenyl 105.1 150.5 AM1284 H 3 OCOCH.sub.3 H 1-naphthyl
126.8 102.8 AM1289 H 3 OTs H 1-naphthyl 359.6 78.64 AM1292 H 3 I H
1-naphthyl 3.1 18.1 AM1294 H 3 NCS H 1-naphthyl 283.3 237.3 AM1282
H 4 OCOCH.sub.3 H 1-naphthyl 133.4 100.8 AM1283 H 4 OH H 1-naphthyl
117.2 196.5 AM1286 H 4 OTs H 1-naphthyl 1509 1289 AM1288 H 4 I H
1-naphthyl 1.3 10.5 AM1291 H 4 NCS H 1-naphthyl 2958 1804 AM1295 H
4 F H 1-naphthyl 2.5 30.7 AM2232 H 4 CN H 1-naphthyl 0.28 1.48
AM2231 NO.sub.2 4 CN H 1-naphthyl 4.90 23.9 AM2202 H 5 OH H
1-naphthyl 33.1 110.6 AM2203 H 5 I H 1-naphthyl 7.8 45.8 AM2204 H 5
NCS H 1-naphthyl 7.5 24.4 AM2201 H 5 F H 1-naphthyl 1.0 2.6 AM1233
NO.sub.2 5 OAc H 1-naphthyl 141.7 153.9 AM1234 NO.sub.2 5 OH H
1-naphthyl 77.6 196.8 AM1235 NO.sub.2 5 F H 1-naphthyl 1.5 20.4
AM1236 NH.sub.2 5 OAc H 1-naphthyl 1127 558.8 AM1237 NH.sub.2 5 OH
H 1-naphthyl 836.8 244.4 AM1238 I 5 OH H 1-naphthyl 3.1 17.3 Am1230
I 5 F H 1-naphthyl 1.1 2.4 AM2210 H 4 I H 4-nitro-1- 1.8 11.3
naphthyl AM2213 H 4 I H 4-azido-1- 3.0 30 naphthyl AM2216 H 4 I H
4-isothicocyano-1- 42.4 213 napthyl AM1256 H 5 H CH.sub.3
4-dimethylamino-1- 4.74 18.6 naphthyl
[0045] The above materials were generally prepared as follows.
A. General Preparation Procedures for Materials Listed in Table
2
[0046] The materials listed in Table 2 can be prepared by methods
outlined in Scheme 1. ##STR5##
[0047] When Z.dbd.NO.sub.2, the structures can be transformed to
the different substituents as listed in Table 2 using methods
outlined in Scheme 2. ##STR6##
[0048] The commercially unavailable R3-COCl used in Scheme 1 can be
prepared according to Scheme 3. ##STR7##
[0049] After these acid chlorides were connected to indole
3-position, the nitro group in them can be further transformed into
amino, iodo, azido, and isothiocyanate groups according to the
methods outlined in Scheme 4. ##STR8## B. General Preparation
Procedures for Materials Listed in Table 1
[0050] These materials can be prepared in similarly manners as
those compounds listed in Table 2 by using
N-methyl-2-piperidinemethyl chloride instead of
acetoxylalkylhalides for the alkylation of indole 1-position in
Scheme 1.
[0051] Examples of specific analogs were prepared as follows:
[0052] 3-Acyl-1H-indole. 17.5 ml of a 3M solution of methyl
magnesium bromide in ethyl ether was added dropwise with stirring
to a solution of indole (5.85 g, 50 mmol) in 50 mL of ethyl ether
at 0.degree. C. After addition, the reaction mixture was warmed up
to room temperature and stirred for 2hours (h). Then the reaction
mixture was cooled down again to 0.degree. C. and to it was added
slowly with violent stirring a solution of acyl chloride (50 mmol)
in 50 mL of ethyl ether. The resulting reaction mixture was warmed
up to room temperature and stirred for another 1 h followed by the
slow addition of 375 ml of ammonium chloride aqueous solution.
After violently stirring for 30 min, a white solid was formed and
filtrated. The filtrate was washed successively with ethyl ether
and recrystallized from ethyl acetate:hexane to afford the
product.
2-methyl-3-acyl-1H-indole. The foregoing procedure was repeated
using 2-methyl indole in place of indole.
[0053] 1-Alkyl-2-methyl-3-acyl-1H-indole. To a 1.2 mmol suspension
of sodium hydride (48 mg, 60% in mineral oil) in 2 mL of
dimethylformamide (DMF) was added 2-methyl-3-acyl-1H-indole (0.4
mmol). After stirring at room temperature for 30 min, alkyl bromide
(0.6 mmol) was added dropwise. The resulting mixture was heated to
65.degree. C. and stirred for 3 h followed by removal of solvent
under vacuum. The residue was separated by flash column
chromatography (silica gel, petroleum ether-ethyl acetate, 5:1,
v/v) to afford the product.
[0054] A person of ordinary skill in the art, understanding the
disclosures for the general preparation and specific preparation
examples would know how to modify the disclosed procedures to
achieve the above listed analogs.
[0055] The materials were tested for CB2 receptor binding affinity
and for CB1 receptor affinity (to determine selectivity for the CB2
receptor). As used herein, "binding affinity" is represented by the
IC.sub.50 value which is the concentration of an analog required to
occupy the 50% of the total number (Bmax) of the receptors. The
lower the IC.sub.50 value the higher the binding affinity. As used
herein an analog is said to have "binding selectivity" if it has
higher binding affinity for one receptor compared to the other
receptor; e.g. a cannabinoid analog which has an IC.sub.50 of 0.1
nM for CB1 and 10 nM for CB2, is 100 times more selective for the
CB1 receptor. The binding affinities (K.sub.i) are expressed in
nanomoles (nM) and are listed in TABLE 1 and TABLE 2 above.
[0056] For the CB1 receptor binding studies, membranes were
prepared from rat forebrain membranes according to the procedure of
P. R. Dodd et al, A Rapid Method for Preparing Synaptosomes:
Comparison with Alternative Procedures, Brain Res., 107-118 (1981).
The binding of the novel analogues to the CB1 cannabinoid receptor
was assessed as described in W. A. Devane et al, Determination and
Characterization of a Cannabinoid Receptor in a Rat Brain, Mol.
Pharmacol., 34, 605-613 (1988) and A. Charalambous et al, 5'-azido
.DELTA..sup.8-THC: A Novel Photoaffinity Label for the Cannabinoid
Receptor, J. Med. Chem., 35, 3076-3079 (1992) with the following
changes. The above articles are incorporated by reference
herein.
[0057] Membranes, previously frozen at -80.degree. C., were thawed
on ice. To the stirred suspension was added three volumes of TME
(25mM Tris-HCl buffer, 5 mM MgCl.sub.2 and 1 mM EDTA) at a pH 7.4.
The suspension was incubated at 4.degree. C. for 30 min. At the end
of the incubation, the membranes were pelleted and washed three
times with TME.
[0058] The treated membranes were subsequently used in the binding
assay described below. Approximately 30 .mu.g of membranes were
incubated in silanized 96-well microtiter plate with TME containing
0.1% essentially fatty acid-free bovine serum albumin (BSA), 0.8 nM
[.sup.3H] CP-55,940, and various concentrations of test materials
at 200.degree. C. for 1 hour. The samples were filtered using
Packard Filtermate 196 and Whatman GF/C filterplates and washed
with wash buffer (TME) containing 0.5% BSA. Radioactivity was
detected using MicroScint 20 scintillation cocktail added directly
to the dried filterplates, and the filterplates were counted using
a Packard Instruments Top-Count. Nonspecific binding was assessed
using 100 nM CP-55,940. Data collected from three independent
experiments performed with duplicate determinations was normalized
between 100% and 0% specific binding for [.sup.3H] CP-55,940,
determined using buffer and 100 nM CP-55,940. The normalized data
was analyzed using a 4-parameter nonlinear logistic equation to
yield IC.sub.50 values. Data from at least two independent
experiments performed in duplicate was used to calculate IC.sub.50
values which were converted to K.sub.i values using the assumptions
of Cheng et al, Relationship Between the Inhibition Constant
(K.sub.i) and the concentration of Inhibitor which causes 50%
Inhibition (IC.sub.50) of an Enzymatic Reaction, Biochem.
Pharmacol., 22, 3099-3102, (1973), which is incorporated by
reference herein.
[0059] For the CB2 receptor binding studies, membranes were
prepared from frozen mouse spleen essentially according to the
procedure of P. R. Dodd et al, A Rapid Method for Preparing
Synaptosomes: Comparison with Alternative Procedures, Brain Res.,
226, 107-118 (1981) which is incorporated by reference herein.
Silanized centrifuge tubes were used throughout to minimize
receptor loss due to adsorption. The CB2 binding assay was
conducted in the same manner as for the CB1 binding assay. The
binding affinities (K.sub.i) were also expressed in nanomoles
(nM).
[0060] The physiological and therapeutic advantages of the
inventive materials can be seen with additional reference to the
following references, the disclosures of which are hereby
incorporated by reference. Arnone M., Maruani J., Chaperon P, et
al, Selective inhibition of sucrose and ethanol intake by SR141716,
an antagonist of central cannabinoid (CB1) receptors,
Psychopharmacal, (1997) 132, 104-106. Colombo G, Agabio R, Diaz G.
et al. Appetite suppression and weight loss after the cannabinoid
antagonist SR141716. Life Sci. (1998) 63-PL13-PL117. Simiand J,
Keane M, Keane P E, Soubrie P: SR 141716, A CB1 cannabinoid
receptor antagonist, selectively reduces sweet food intake in
marmoset. Behav. Pharmacol (1998) 9:179-181. Brotchie J M: Adjuncts
to dopamine replacement a pragmatic approach to reducing the
problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998)
13:871-876. Terranova J-P, Storme J-J Lafon N et al: Improvement of
memory in rodents by the selective CB1 cannabinoid receptor
antagonist, SR 141716. Psycho-pharmacol (1996) 126:165-172. Hampson
A L Grimaldi M. Axpirod J. Wink D: Cannabidiol and (-)
.DELTA..sup.9 tetrahydrocannabinol are neuroprotective
antioxidants. Proc. Natl Acad Sci. USA (1998) 9S:8268-8273. Buckley
N E, McCoy K I, Mpzey E et al Immunomodulation by cannabinoids is
absent in mice deficient for the cannabinoid CB.sub.2 receptor.
Eur. J Pharmacol (2000) 396:141-149. Morgan Dr: Therapeutic Uses of
Cannabis. Harwood Academic Publishers, Amsterdam. (1997). Joy J E,
Wagtson S J, Benson J A: Marijuana and Medicine Assessing the
Science Base. National Academy Press, Washington, DC, USA (1999).
Shen M. Thayer S A: Cannabinoid receptor agonists protect cultured
rat hippocampal neurons from excitotoxicity. Mol. Pharmacol (1996)
54:459-462. DePetrocellis L, Melck D, Palmisano A. et al: The
endogenous cannabinoid anandamide inhibits human breast cancer cell
proliferation. Proc Natl. Acad. Sci USA (1998) 95:8375-8380. Green
K. Marijuana smoking vs. cannabinoids for glaucoma therapy. Arch.
Ophibalmol. (1998) feb 433-1437. Hemming M, Yellowlees P M,
Effective treatment of Tourette's syndrome with marijuana. J.
Psychopharmacol, (1993) 7:389-391. Muller-Vahl K B, Schneider U,
Kolbe H, Emrich, H M. Treatment of Tourette's syndrome with
delta-9-tetrahydrocannabinol. Am. J. Psychiat. (1999) 156-195.
Muller-Vahl K B, Kolbe H, Schneider U, Emrich, H M Cannabis in
movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3)
23-27. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The
perceived effects of smoked cannabis on patents with multiple
sclerosis, Eur. Neurol. (1997) 38-44-48. Pinnegan-Ling D, Musty R.
Marinol and phantom limb pain: a case study. Proc Inv. Cannabinoid
Rea. Sec. (1994):53. Brenneisen R, Pgli A, Elsohly M A, Henn V.
Spiess Y: The effect of orally and rectally administered
.DELTA..sup.9-tetrahydrocannabinol on spasticity, a pilot study
with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452.
Martyn C N. Illis L S, Thom J. Nabilone in the treatment of
multiple sclerosis. Lancet (1995) 345:579. Maurer M, Henn V,
Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows
antispastic and analgesic effects in a single case double-blind
trial. Eur. Arch. Psychiat. Clin. Neurosci. (1990), Z40:1-4.
Herzberg U, Eliav E, Bennett G J, Kopin I J: The analgesic effects
of R(+) WIN 55,212-2 mesylate, a high affinity cannabinoid agonist
in a rare model of neuropathic pain. Neurosci. Letts. (1997)
221:157-160. Richardson J D, Kilo S. Hargreaves K M, Cannabinoids
reduce dryperalgesia and inflammation via interaction with
peripheral CB1 receptors. Pain (1998) 75:111-119. Ricardson J D,
Aanonsen I, Hargreaves K M: Antihyperalgesic effects of a spinal
cannabinoids. Eur. J. Pharmacol. (1998) 346:145-153. Calignano A,
La Rana G. Diuffrida A, Piomelli D: Control of pain initiation by
endogenous cannabinoids. Nature (1998) 394:277-291. Wagner J A,
Varga K, Jarai Z, Kunos G: Mesenteric vasodilation mediated by
endothelia anandamide receptors. Hypertension (1999) 33:429-434.
Schuel, H., Burkman, L. J., Picone, R. P., Bo, T., Makriyannis, A.,
Cannabinoid receptors in human sperm. Mol. Biol. Cell., (1997) (8),
325a.
[0061] As can be seen from the results in the TABLES, some of the
compounds, for example, AM1295, AM1235, AM1288 and AM694, show a
high selectivity for the CB1 receptor. Other compounds, for
example, AM2230, AM1289, and AM1237, show a high selectivity for
the CB2 receptor. The inventive analogs described herein, and
physiologically acceptable salts thereof, have high potential when
administered in therapeutically effective amounts for providing a
physiological effect useful to treat pain, peripheral pain,
glaucoma, epilepsy, nausea such as associated with cancer
chemotherapy, AIDS Wasting Syndrome, cancer, neurodegenerative
diseases including Multiple Sclerosis, Parkinson's Disease,
Huntington's Chorea and Alzheimer's Disease, mental disorders such
as Schizophrenia and depression; to prevent or reduce endotoxic
shock and hypotensive shock; to modulate appetite; to reduce
fertility; to prevent or reduce diseases associated with motor
function such as Tourette's syndrome; to prevent or reduce
inflammation; to provide neuroprotection and to effect memory
enhancement. Thus, another aspect of the invention is the
administration of a therapeutically effective amount of an
inventive compound, or a physiologically acceptable salt thereof,
to an individual or animal to provide a physiological effect.
[0062] In addition, some of the iodide and fluoride containing
compounds, for example, AM694 and AM1230, are potential radioactive
probes which would be useful for imaging in vivo the distribution
of cannabinoid receptors. Further, azido containing compounds, for
example, AM2212, AM2213 and AM1224, would be useful as affinity
probes for characterizing binding pockets of cannabinoid
receptors.
[0063] Those skilled in the art will recognize, or be able to
ascertain with no more than routine experimentation, many
equivalents to the specific embodiments of the invention disclosed
herein. Such equivalents are intended to be encompassed by the
scope of the invention.
* * * * *